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Abstract
The plasma membrane Hq-ATPase is a promising new antifungal target that is readily probed with the sulfhydryl-reac-
tive reagent omeprazole. Inhibition of the Hq-ATPase by omeprazole is closely linked to cell killing, and it has been
suggested that enzyme inhibition may result from a covalent interaction within the first two transmembrane segments M1
.   . .and M2 Monk et al. 1995 Biochim. Biophys. Acta 1239, 81–90 . In this study, the molecular nature of this interaction
was examined by screening a series of 26 well-characterized pma1 mutations residing in the first two transmembrane
segments of the Hq-ATPase from Saccharomyces cere˝isiae. Only two pma1 mutants, A135G and G158D,G156C, were
found to significantly decrease the sensitivity of cells for omeprazole. In contrast, enhanced sensitivity was observed at a
 .number of positions, with D140C A and M128C producing the most significant increases in sensitivity. The introduction of
cysteine at various locations within this region only marginally affected omeprazole sensitivity, suggesting that this region
was not a direct site of covalent modification. Rather, its conformation influences omeprazole binding at some other locus.
In order to determine the sidedness of the omeprazole interaction, a novel in vitro assay system was exploited that utilized
liposomes co-reconstituted with the Hq-ATPase and the light-driven proton pump bacteriorhodopsin. Omeprazole was
found to completely inhibit proton transport by the Hq-ATPase at 50 mM in this system. An asymmetrically-distributed
chemical trap system involving glutathione was used to demonstrate that this inhibition appears localized to the extracellular
portion of the enzyme. This work indicates that omeprazole can inhibit the Hq-ATPase from its extracellular face, and this
inhibition is influenced by changes in the M1, M2 region of the protein.
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1. Introduction
Opportunistic fungal infections are widespread in
HIV and other immunosuppressed individuals, and
are a growing problem for the management of such
patients. Candida albicans, which causes both mu-
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cosal and invasive disease, is the predominant organ-
ism associated with fungal disease, although other
fungal pathogens such as Aspergillus fumigatus,
Cryptococcus neoformans, Pneumocystis carinii,
Histoplasma capsulatum, and other Candida species
w xare increasingly important 1,2 . Mucosal fungal in-
fections can be treated with existing azole-based anti-
fungals, although fewer treatment options are avail-
able for invasive disease, which usually requires ther-
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apy with the highly nephrotoxic polyene antibiotic
w xamphotericin B 3 . In addition to the problem of
invasive disease, a major concern is the increasing
number of azole-related treatment failures due to both
induction of resistance in Candida albicans and to
wcolonization by less susceptible Candida species 4–
x6 . There exists a critical need to identify novel
antifungal targets that can be used to develop new
mechanistic classes of therapeutics, which can effec-
tively circumvent such problems.
The plasma membrane proton pumping Hq-ATPase
is an important new target for therapeutic interven-
w x qtion 7 . The H -ATPase is a predominant membrane
protein that belongs to the P-type ATPase family of
ion translocating ATPases. This essential enzyme
plays a critical role in fungal cell physiology by
maintaining the large transmembrane electrochemical
proton gradient necessary for nutrient uptake and by
w xregulating intracellular pH 8 . It is one of the few
antifungal targets which have been demonstrated to
w xbe essential by gene disruption 9 . In addition to its
role in cell growth, the Hq-ATPase has been impli-
cated in fungal pathogenicity through its effects on
w xdimorphism 10,11 , nutrient uptake, and medium
w xacidification 12 .
The family of P-type ion pumps includes the
Naq,Kq-ATPase and Hq,Kq-ATPase, which are
molecular targets for several clinically-important
w xtherapeutics 13,14 . These drugs are enzyme-specific
antagonists, which inhibit via an interaction with the
extracellular surface of their respective target en-
zyme. These precedents suggest that it should be
possible to develop similar types of antagonists spe-
cific for the fungal Hq-ATPase. Highly specific Hq-
ATPase antagonists capable of acting from outside
the cell should be extremely valuable as antifungals.
This is especially pertinent given the increasing clini-
cal problem of drug resistance due to multi-drug
r w xresistance pumps, such as CDR1 and BEN 4 . Ex-
tracellularly-directed reagents do not cross the cellu-
lar membrane, and therefore are not substrates for
these high capacity drug pumps.
Recently, we demonstrated the importance of the
Hq-ATPase as an antifungal target by showing that
inhibition of the enzyme by the sulphydryl-reactive
reagent omeprazole was closely correlated with inhi-
bition of cell growth by Candida albicans and Sac-
charomyces cere˝isiae, and that omeprazole-induced
w xinhibition of the proton pump was fungicidal 15 .
Although not suitable as a therapeutic antifungal
agent, omeprazole showed well defined and con-
trolled properties that made it a valuable probe to
examine the role of the Hq-ATPase as a molecular
target. Consistent with studies of the action of
omeprazole on the gastric Hq,Kq-ATPase, omepra-
zole-induced inhibition of the fungal Hq-ATPase was
suggested to result from a drug interaction with the
extracellular surface of the enzyme. Mutant analysis
of the Saccharomyces cere˝isiae enzyme indicated
that amino acid residues in M1 and M2 may be
w ximportant for omeprazole-induced inhibition 15,16 .
In this work, we explore in more detail the molecular
interaction of omeprazole with the Hq-ATPase.
2. Materials and methods
2.1. Cell strains and cell growth
w xHalobacterium halobium strain S9 17 was grown
at 378C for one week in 175 ml of growth medium
consisting of 1% bacto-yeast extract, 2.5% bacto-
tryptone, 4.4 M NaCl, 40 mM MgSO , 67 mM KCl,4
and 1.3 mM CaCl . A 10-ml volume of this culture2
was used to inoculate 2 liters of growth medium in a
2.8-l Fernbach flask. The cultures were grown 2–3
weeks at 378C on a gyrator shaker at very slow speed
 .25 rpm to limit aeration. All Saccharomyces cere-
˝isiae strains utilized in this study were isogenic
( ) w xderivatives of Y55 HO gal3 MAL1 SUC1 18 and
w xmost have been described 19–21 . pma1 strains
containing cysteine mutations were prepared as previ-
w xously described 19 . The wild-type strain GW201
(HO ade6-1 trp5-1 leu2-1 lys1-1 ura3-
)1PMA1::URA3 was used as a control strain. All
yeast cell cultures were grown at 228C in YPD
medium containing 1% yeast extract, 2% peptone and
 .2% dextrose pH 5.7 . In vivo drug sensitivities were
w xdetermined as described by Monk et al. 15 .
2.2. Preparation of bacteriorhodopsin membranes
Halobacterium cells were collected by centrifuga-
tion at 10 000=g for 10 min. The cells were washed
by resuspension with 40 ml wash buffer containing
 .10 mM Tris-HCl pH 7.0 and 4.0 M NaCl and then
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centrifugation, as above. The cells were osmotically
lysed in 120 ml lysis buffer containing 10 mM
 .Tris-HCl pH 7.0 , 100 mM NaCl and 1 mM NaN3
and 0.13 mgrml DNAse I. The suspension was
centrifuged at 5000=g for 10 min, and the super-
natant was removed and centrifuged at 40 000=g
for 15 min. The pellets were washed by resuspension
and centrifugation, as above. Purple membranes were
resuspended with storage buffer consisting of 10
 .mM Tris-HCl pH 7.0 , 100 mM NaCl, 1 mM NaN3
and 20% glycerol, and stored at y808C.
2.3. Isolation and reconstitution of yeast H q-ATPase
Microsomal membranes, prepared by the method
w xof Perlin and Brown 22 , were extracted with 0.48%
 .wrv deoxycholate in solubilization buffer contain-
 .ing 10 mM Hepes-KOH pH 7.0 , 0.1 M KCl, 45%
 .vrv glycerol, 0.2 mM EDTA, 1 mM dithiothreitol,
1 mgrml asolectin and 1 mgrml brain extract Folch
Fraction III containing 80–85% phosphatidyl-serine;
.Sigma Co. . The extracted membranes were resus-
pended with 25 ml of solubilization buffer supple-
mented with 0.5 M KCl, and centrifuged at 250 000
=g for 1 h. The KCl-washed membranes were
resuspended at 0.5 mgrml in 1 ml solubilization
buffer containing 20 mgrml asolectin. Deoxycholate
was added with gentle stirring to a final concentration
 .of 0.48% wrv by dropwise addition from a 10%
 .wrv stock solution. The mixture was placed on ice
for 5 min and then diluted into 50 ml of ice-cold
dilution buffer containing 5 mM Hepes-KOH pH
.7.0 and 100 mM KCl. The reconstituted vesicles
were recovered by centrifugation at 250 000=g for
1 h. The reconstituted liposomes were resuspended in
25 ml dilution buffer and then pelleted by centrifuga-
tion, as above. The final pellets were resuspended in
0.2 ml of dilution buffer.
2.4. Co-reconstitution of bacteriorhodopsin and H q-
ATPase
A 50 ml volume of reconstituted Hq-ATPase-con-
 .taining vesicles 100–200 mg were mixed with 10
 .ml of bacteriorhodopsin membranes 20 mg and 60
ml of 2 M NaCl. The mixture was frozen on dry ice
for 10 min and then thawed at 228C for 10 min. This
procedure was repeated twice. The vesicles were
briefly sonicated for 10 s in a sonic bath Model
G112PIT, Laboratory Supplies Co., Inc., at 80 kHz
.and 80 W .
2.5. Proton transport measurements
Proton transport in reconstituted vesicles was fol-
lowed using the acridine orange fluorescence quench-
w xing assay 23 . The assay medium consisted of 2 ml
 .of 5 mM Hepes-KOH pH 7.0 , 1 M NaCl, 4 mM
acridine orange and 100–200 mg of the reconstituted
vesicles. Light driven proton transport was initiated
by applying high-intensity actinic light Fiber-Lite,
.Dolan-Jenner Industries, Inc to activate the bacterio-
rhodopsin pump, as described by Oesterhelt and
w xStoeckenius 17 . ATP driven proton pumping was
initiated by the sequential addition of 5 mM ATP and
1 mM MgCl . Relative fluorescence was monitored2
with a Perkin-Elmer LS-5B Luminescence Spec-
trophotometer using excitation and emission wave-
lengths of 419 and 520 nm, respectively. An interfer-
ence filter-transmitting light of l less than 555 nm
was placed in front of the detector and a filter
blocking actinic light above 597 nm was placed in
front of the sample. The magnitude of the pH gradi-
ent formed in light by bacteriorhodopsin was deter-
mined with the indicator dye dicarboxy-dichlorofluo-
 .rescein CDCF . Co-reconstituted bacteriorhodopsin
and Hq-ATPase liposomes were resuspended in 2 ml
 .of buffer containing 5 mM Hepes-KOH pH 7.0 , 1
M NaCl, and 0.05 mM CDCF. Bacteriorhodopsin-in-
duced proton pumping was initiated by the addition
 .of light see above for 10 min. Calibration of pH
was accomplished by evaluating the shift in the fluo-
rescence spectrum for CDCF as a function of pH
w x24 . Vesicles were pre-equilibrated at varying pH
 .values pH 3.0–7.0 in the presence of 10 mM NH Cl4
to collapse any residual pH gradients. A series of
spectra reflecting the different pH values was ob-
tained by varying the excitation wavelength from 400
to 500 nm at a fixed emission wavelength of 510 nm
w x24 .
2.6. Other procedures
ATP hydrolysis measurements were performed in
a 96-well plate assay in a 100 ml volume containing
 .10 mM Mes-Tris pH 6.4 , 25 mM NH Cl, 5 mM4
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ATP, 5 mM MgCl , 0.5 mM NaN , and 1 mg yeast2 3
plasma membranes, as described by Seto-Young et
w xal. 19 . Protein concentration was determined by a
w xmodified Lowry method 25 .
3. Results
( ) ( )3.1. Amino acid modulation in M1 and M2 alters
cell growth inhibition by omeprazole
It was previously demonstrated that omeprazole-
induced antagonism of the plasma membrane Hq-
ATPase was influenced by structural changes in M1
w xand M2 15 . To further investigate the role of this
region in omeprazole-induced antagonism, a series of
Saccharomyces cere˝isiae pma1 mutants with well
w xcharacterized mutations in M1, M2 19,20 were
screened for drug-induced changes in growth inhibi-
tion profiles. Cells were grown in YPD at pH 3.5
with omeprazole from 0 to 250 mM, which was
previously shown to impart selectivity for the Hq-
w xATPase 15 . Fig. 1A summarizes growth inhibition
data for the various mutants. It can be seen that
mutations at several positions in M1, M2 increased
the sensitivity of cells to omeprazole. In contrast,
only two mutations, A135G and a double mutant,
G158D,G156C, were found to significantly decrease
the sensitivity of cells for omeprazole, as previously
w xreported 15 . Many mutations were without effect.
The enhanced sensitivities observed were not due to
deficiencies in growth, since all the mutants had
 .growth rates comparable to wild-type not shown .
These results suggest that modification of amino acid
side groups in M1, M2 result in a modulation of
omeprazole-induced inhibition of the Hq-ATPase.
Omeprazole is highly reactive with the -SH side
group moiety of cysteine, although it does not appear
w xto interact with C148 in M2 16 . To examine whether
cysteine at other positions in this region could inter-
act with omeprazole, a series of pma1 mutants was
constructed that included I124C, M128C, A132C,
A136C, G137C, S139C, D140C and W141C. Fig. 1B
shows that introduction cysteine at various positions
enhanced the sensitivity of cells to omeprazole. The
most significant enhancement was observed with
D140C, which lies on the external loop region linking
M1 and M2. This suggested that mutant enzyme
containing C140 interacts more strongly with
omeprazole than wild-type. However, it is not likely
w xFig. 1. Growth effect of omeprazole on pmal mutants. A: A series of well-characterized mutations in the M1 and M2 19–21 were
screened for changes in omeprazole-dependent growth inhibition by inoculating log-phase cells in YPD medium at pH 3.5 containing
 .increasing amounts of omeprazole 0–250 mM . B: A set of cysteine mutants were constructed, as described in Section 2, and were
screened as described above. The inhibition profile for wild-type was taken as the control.
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to occur directly at this position because the introduc-
tion of alanine at D140 produced a similar effect
 .Fig. 1A . Three cysteines, C148, C312 and C867,
are predicted to lie either within the membrane sector
w xor near it 26 . Yet, none of these residues appear to
be responsible for omeprazole interactions because
each can be converted to either alanine or serine
w xwithout altering omeprazole sensitivity 15 . This
conclusion was further supported by showing that
simultaneous conversion of two cysteines
 .C148S,C312S; C148S,C867A; C312S,C867A or all
 .three cysteines C148S,C312S,C867A had no effect
 .on omeprazole sensitivity data not shown . Thus,
other cysteine residues may be involved in omepra-
zole-induced enzyme antagonism.
3.2. Assessing sidedness of omeprazole action
An important aspect of developing the Hq-ATPase
as an antifungal target is that inhibition of the en-
zyme should be possible from the extracellular sur-
face of the enzyme. Omeprazole is a good reagent to
explore this possibility because it has properties which
allow for interactions in selective environments. In
the presence of acid, omeprazole forms a short-lived
and highly reactive sulfenamide moiety that reacts in
its local environment. This property has been impor-
tant for selective inhibition of the gastric Hq,Kq-
w xATPase 14 . A novel in vitro assay adapted from
w xWach et al. 27 was used to investigate whether
omeprazole-induced antagonism of the Hq-ATPase
occurs from the extracellular portion of the enzyme.
In this assay, which is illustrated in Fig. 2A, the
 .light-driven proton pump bacteriorhodopsin BR is
used to acidify the intravesicular space of liposomes
co-reconstituted with BR and the Hq-ATPase, thereby
activating omeprazole partitioned in this compart-
ment. At neutral pH, omeprazole is unreactive and
freely permeant across the bilayer. However, in the
presence of acid, a charged sulfenamide species is
formed that is essentially impermeant across the bi-
layer. Following a period of acid-activation, Mg-ATP
is added to the reconstituted vesicles to assess the
efficiency of ATP-driven pH gradient formation by
the Hq-ATPase, as illustrated by the quenching of
 .acridine orange fluorescence Fig. 2B . Even though
the Hq-ATPase reconstitutes in an equal orientation,
only those enzymes with the active site cytoplasmic
Fig. 2. Schematic diagram of in vitro assay system. A: Diagram
illustrates a liposome co-reconstituted with bacteriorhodopsin
 . qBR and the H -ATPase. The introduction of an actinic light
pulse initiates proton pumping by BR that results in an interior
acid pH gradient. The acidic interior pH activates omeprazole
which then interacts with the Hq-ATPase. B: In a typical experi-
ment, co-reconstituted vesicles are added to 2-ml buffer contain-
 .ing 5 mM Hepes pH 7.0 , 1 M NaCl, 5 mM ATP, and 4 mM
acridine orange. In the presence of an actinic light, interior acid
pH gradients are formed as shown by the quenching of acridine
orange fluorescence. Proton transport by the Hq-ATPase is as-
sessed by the addition of 5 mM MgCl . The pH gradients formed2
can be dissipated by the addition of 10 mM NH Cl, as indicated.4
.portion of the enzyme on the extracellular surface of
the vesicles are active in this assay. Thus, it is
possible to observe sidedness properties of the acti-
vated compound. The relative level of intravesicular
acidification was determined by using the pH-sensi-
 .tive probe dicarboxy-dichlorofluorescein CDCF .
CDCF is sensitive to pH at wavelengths above 450
nm with optimal differential sensitivity at 480–490
w xnm 24 . The probe was calibrated by observing the
fluorescence emission spectrum in vesicle prepara-
tions equilibrated in the pH range 3.5 to 7.0. In the
presence of actinic light, the intravesicular space of
the co-reconstituted BR-HqATPa vesicles were acid-
ified down to approx. pH 3.9–4.3.
Fig. 3 shows the dose-response for omeprazole-in-
duced inhibition of ATP-mediated proton transport
by the Hq-ATPase following a 10-min actinic light
pretreatment. The observed inhibition was fully de-
pendent on acid conversion of omeprazole catalyzed
by bacteriorhodposin, since dark pretreatment did not
lead to specific inhibition of proton transport.
Omeprazole was found to completely inhibit trans-
port by the Hq-ATPase at 50 mM. There were only
minor effects on light-induced proton pumping by
 .bacteriorhodopsin under these conditions not shown .
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Fig. 3. Dose-dependent inhibition of proton transport of Hq-
ATPase by omeprazole. Vesicles co-reconstituted with Hq-
ATPase and bacteriorhodopsin were incubated with omeprazole
at 0–50 mM, as indicated, in a buffer containing 5 mM Hepes
 .pH 7.0 , 1 NaCl and 4 mM acridine orange. The vesicles were
pretreated with actinic light for 10 min, left in the dark for 5 min,
and then 5 mM Mg-ATP was used to initiated proton transport by
Hq-ATPase.
The reactive sulfenamide produced as a result of
acid activation of omeprazole should be localized to
the intravesicular surface of the enzyme. To rule out
the possibility that a small fraction of the reactive
species crossed the bilayer and reacted at the catalytic
 .site of the enzyme, a large molar excess 25-fold of
agarose-conjugated glutathione relative to activated
omeprazole was added to the assay mixture. It was
assumed that less than 5% of the omeprazole present
would be converted to the sulfenamide form at ;pH
.4.0. Glutathione effectively protects against the ac-
w xtion of omeprazole, as previously demonstrated 15 .
When coupled to agarose, it cannot cross the bilayer
and is essentially localized to the extravesicular com-
partment of the reconstituted vesicles. If any active
sulfenamide molecules crossed the bilayer, they would
rapidly react with the large excess of glutathione,
which served as a chemical trap. Fig. 4 shows that
light-induced inhibition of the Hq-ATPase was com-
pletely unaffected by the presence of glutathione-
agarose, even at a high level of omeprazole 100
.mM , which caused a slight non-specific diminution
of the pH gradient. In contrast, permeant sulphydryl
reagents were completely effective in protecting the
enzyme against omeprazole-induced inactivation not
.shown . Typically, omeprazole-inhibited enzyme was
Fig. 4. Effect of Glutathione-agarose on omeprazole-induction inhibition of Hq-ATPase Co-reconstituted vesicles were assayed for
ATP-mediated proton transport, as described in Fig. 3. The vesicles were incubated in the presence or absence of 100 mM omeprazole
and 250mM glutathione-agarose, prior to 10 min actinic light treatment, as shown.
( )D. Seto-Young et al.rBiochimica et Biophysica Acta 1326 1997 249–256 255
 .only partially reactivated -40% following treat-
ment with 2-mercaptoethanol. Partial reactivation may
have resulted from inhibited enzyme forming a highly
perturbed conformation or from the modification of
multiple sites with differential chemical accessibility
once modified. The covalent nature of the inhibition
was further demonstrated by showing that the en-
zyme remained fully inhibited following centrifuga-
tion andror dilution with reaction buffer. These re-
sults suggest that inhibition of the Hq-ATPase most
likely occurs from the intravesicular face of the en-
zyme, and it is mediated by covalent linkage to one
or more cysteine residues.
4. Discussion
4.1. Enzyme inhibition is mediated by the extracellu-
lar portion of the H q-ATPase
In this report, we provide evidence from a novel in
vitro assay system that Hq-ATPase function can be
blocked when a positively charged sulfenamide de-
rived from omeprazole interacts with the extracellular
portion of the Hq-ATPase. This result is consistent
with the sided interaction of omeprazole and
SCH28080 on the Hq,Kq-ATPase of gastric parietal
w xcells 14,28 and of cardiac glycosides with the
q q w xNa ,K -ATPase of red blood cells 29 . The P-type
ATPases in the plasma membrane expose only a
 .small portion -10% of their total mass at the
w xextracellular surface 30 . Nonetheless, therapeutics
which target these enzymes are highly selective.
Omeprazole-induced inhibition of the fungal Hq-
ATPase does not involve the same local interaction
site as the gastric Hq,Kq-ATPase, since the cysteine
residues involved in inhibition of that enzyme are not
w xconserved in the fungal enzyme 15 . Our experi-
ments raise the distinct possibility that water-soluble
antagonists targeting the fungal enzyme can be iden-
tified. Such reagents would be desirable because
inhibition of the enzyme from the extracellular sur-
face of the membrane would effectively eliminate
drug resistance problems due to high capacity drug
efflux pumps, which are associated with azole resis-
w xtance of clinical isolates of Candida albicans 4 . A
clearer understanding of the mechanism of sulfe-
namide-dependent inhibition of the Hq-ATPase could
help identify a cell surface target region suitable for
drug discovery purposes.
4.2. M1 and M2 can modulate omeprazole-dependent
inhibition of the H q-ATPase
It is well established that modification of amino
acid side groups in M1, M2 can alter the local
w xstructure of this region 19,20 . The role of local
perturbations in M1, M2 on omeprazole-induced inhi-
bition was examined by surveying a series of well
characterized mutations in this region. Many of the
mutations enhanced the sensitivity of cells to omepra-
 .zole Fig. 1A , although the most prominent effects
were observed for M128C in M1 and D140A or
D140C in the extracellular loop region joining M1
 .and M2 Fig. 1A,B . In contrast, only one mutant,
G158D,G156C, near the cytoplasmic end of M2 was
shown to confer significant insensitivity to omepra-
zole. It was not possible to examine this mutant
enzyme in the in vitro assay system because it did not
show reconstituted proton transport. These results
suggest that perturbations in the hairpin region alter
the omeprazole interaction with the Hq-ATPase.
While it is not yet possible to determine whether
these effects are direct or indirect, M1 and M2 are
believed to be important regions of therapeutic inter-
action for cardiac glycosides in the Naq,Kq-ATPase
w x31,32 and reversible inhibitors like SCH28080 in
q q w xthe gastric H ,K -ATPase 28 . This region of the
enzyme is highly conformationally active and appears
to be coupled to the catalytic active site domain
w x33,34 . Thus, the hairpin region formed by M1 and
M2 could represent an important interaction region
on the fungal Hq-ATPase for therapeutic interven-
tion, as has been observed for therapeutics to higher
enzymes. The hairpin structure appears to be a con-
served structural motif for all P-type ATPases. How-
ever, the specificity of the various therapeutics for
individual enzymes, which may vary by 3–4 orders
w xof magnitude 32 , appears to lie in the turn region;
this region varies between all the different eukaryotic
w xenzymes 35 . While M1, M2 may affect an interac-
tion domain for the omeprazole-generated sulfe-
namide, it does not appear to be the site of covalent
modification. Conserved residue C148 in M2 had
earlier been suggested to be a possible primary site of
w xinteraction for omeprazole 15 . It was recently shown
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in a different strain background that C148S, as well
as two other putative membrane sector sulfhydryl
groups, C312 and C867, are not involved in omepra-
w xzole inhibition of cell growth 16 . In this study we
showed that the incorporation of cysteine at various
positions within this region had little impact, except
at positions D140 and M128. However, there is no
evidence for a direct interaction of omeprazole at
these sites. Thus, it is appears more likely that the
site of covalent interaction by omeprazole lies in a
different portion of the external domain of the
molecule. Identifying the region containing that
 .residue s will be an important goal toward defining a
useful drug target site on the Hq-ATPase.
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